Bristol-Myers Squibb Company (BMY) is a leading drug manufacturers - general business with stocks listed in the US. It opened the day at US$50.26 after a previous close of US$50.16. During the day the price has varied from a low of USD50.09 to a high of USD50.535. The latest price was USD50.31 (25 minute delay). Bristol-Myers Squibb Company is listed on the NYSE. All prices are listed in US Dollars.
Our top pick for
US stocks
Our top pick for
Low costs
Our top pick for
Dividend investing
Bristol-Myers Squibb Company's shares were split on a 1000000:95 basis on 7 August 2001. So if you had owned 95 shares the day before the split, the next day you would own 1000000 shares. This wouldn't directly have changed the overall worth of your Bristol-Myers Squibb Company shares – just the quantity. However, indirectly, the new 100% lower share price could have impacted the market appetite for Bristol-Myers Squibb Company shares which in turn could have impacted Bristol-Myers Squibb Company's share price.
| Open | US$50.26 |
|---|---|
| High | US$50.535 |
| Low | US$50.09 |
| Close | US$50.31 |
| Previous close | US$50.16 |
| Change | US$0.15 |
| Change % | 0.299% |
| Volume | 10,093,230 |
| 52-week range | US$48.25 - US$77.8938 |
|---|---|
| 50-day moving average | US$53.7626 |
| 200-day moving average | US$62.383 |
| Target price | US$63.23 |
| PE ratio | 12.6853 |
| Dividend yield | US$2.28 (4.55%) |
| Earnings per share (TTM) | US$3.94 |
Use the fields above to explore the returns from a historical investment. Please refer to the charts further up this page to see performance over 5 years, or other periods. Past performance doesn't indicate future results. Capital is at risk.
Historical closes compared with the last close of $50.31
| 1 week (2023-11-30) | 1.88% |
|---|---|
| 1 month (2023-11-10) | -0.59% |
| 3 months (2023-09-08) | -17.28% |
| 6 months (2023-06-09) | -22.36% |
| 1 year (2022-12-09) | -36.18% |
|---|---|
| 2 years (2021-12-10) | -10.73% |
| 3 years (2020-12-10) | -16.43% |
| 5 years (2018-12-10) | -4.32% |
The technical analysis gauge below displays real-time ratings for the timeframes you select. However, this is not a recommendation. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
Valuing Bristol-Myers Squibb Company stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Bristol-Myers Squibb Company's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Bristol-Myers Squibb Company's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 13x. In other words, Bristol-Myers Squibb Company shares trade at around 13x recent earnings.
That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.
Bristol-Myers Squibb Company's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 0.5948. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Bristol-Myers Squibb Company's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
Bristol-Myers Squibb Company's EBITDA (earnings before interest, taxes, depreciation and amortisation) is US$18.3 billion (£14.6 billion).
The EBITDA is a measure of a Bristol-Myers Squibb Company's overall financial performance and is widely used to measure stock profitability.
Over the last 12 months, Bristol-Myers Squibb Company's shares have ranged in value from as little as US$48.25 up to US$77.8938. A popular way to gauge a stock's volatility is its "beta".
Beta measures a share's volatility in relation to the market. The market (NYSE average) beta is 1, while Bristol-Myers Squibb Company's is 0.333. This would suggest that Bristol-Myers Squibb Company's shares are less volatile than average (for this exchange).
| Revenue TTM | US$44.9 billion |
|---|---|
| Operating margin TTM | 19.19% |
| Gross profit TTM | US$36.4 billion |
| Return on assets TTM | 5.59% |
| Return on equity TTM | 26.87% |
| Profit margin | 18.44% |
| Book value | 14.257 |
| Market capitalisation | US$101.7 billion |
TTM: trailing 12 months
Dividend payout ratio: 29.92% of net profits
Recently Bristol-Myers Squibb Company has paid out, on average, around 29.92% of net profits as dividends. That has enabled analysts to estimate a "forward annual dividend yield" of 4.55% of the current stock value. This means that over a year, based on recent payouts (which are sadly no guarantee of future payouts), Bristol-Myers Squibb Company shareholders could enjoy a 4.55% return on their shares, in the form of dividend payments. In Bristol-Myers Squibb Company's case, that would currently equate to about $2.28 per share.
While Bristol-Myers Squibb Company's payout ratio might seem fairly standard, it's worth remembering that Bristol-Myers Squibb Company may be investing much of the rest of its net profits in future growth.
Bristol-Myers Squibb Company's most recent dividend payout was on 1 November 2023. The latest dividend was paid out to all shareholders who bought their shares by 5 October 2023 (the "ex-dividend date").
Environmental, social and governance (known as ESG) criteria are a set of three factors used to measure the sustainability and social impact of companies like Bristol-Myers Squibb Company.
When it comes to ESG scores, lower is better, and lower scores are generally associated with lower risk for would-be investors.
Total ESG risk: 29.16
Socially conscious investors use ESG scores to screen how an investment aligns with their worldview, and Bristol-Myers Squibb Company's overall score of 29.16 (as at 01/01/2019) is nothing to write home about – landing it in it in the 53rd percentile of companies rated in the same sector.
ESG scores are increasingly used to estimate the level of risk a company like Bristol-Myers Squibb Company is exposed to within the areas of "environmental" (carbon footprint, resource use etc.), "social" (health and safety, human rights etc.), and "governance" (anti-corruption, tax transparency etc.).
Environmental score: 3.83/100
Bristol-Myers Squibb Company's environmental score of 3.83 puts it squarely in the 4th percentile of companies rated in the same sector. This could suggest that Bristol-Myers Squibb Company is a leader in its sector terms of its environmental impact, and exposed to a lower level of risk.
Social score: 18.82/100
Bristol-Myers Squibb Company's social score of 18.82 puts it squarely in the 4th percentile of companies rated in the same sector. This could suggest that Bristol-Myers Squibb Company is a leader in its sector when it comes to taking good care of its workforce and the communities it impacts.
Governance score: 14.02/100
Bristol-Myers Squibb Company's governance score puts it squarely in the 4th percentile of companies rated in the same sector. That could suggest that Bristol-Myers Squibb Company is a leader in its sector when it comes to responsible management and strategy, and exposed to a lower level of risk.
Controversy score: 2/5
ESG scores also evaluate any incidences of controversy that a company has been involved in. Bristol-Myers Squibb Company scored a 2 out of 5 for controversy – the second-highest score possible, reflecting that Bristol-Myers Squibb Company has, for the most part, managed to keep its nose clean.
Bristol-Myers Squibb Company was last rated for ESG on: 2019-01-01.
| Total ESG score | 29.16 |
|---|---|
| Total ESG percentile | 52.58 |
| Environmental score | 3.83 |
| Environmental score percentile | 4 |
| Social score | 18.82 |
| Social score percentile | 4 |
| Governance score | 14.02 |
| Governance score percentile | 4 |
| Level of controversy | 2 |
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis, an oral inhibitor for reduction in risk of stroke/systemic embolism in NVAF, and for the treatment of DVT/PE; Opdivo for anti-cancer indications; Pomalyst/Imnovid indicated for patients with multiple myeloma; Orencia for adult patients with active RA and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia. It also provides Yervoy for the treatment of patients with unresectable or metastatic melanoma; Empliciti for the treatment of multiple myeloma; Abecma for the treatment of relapsed or refractory multiple myeloma; Reblozyl for the treatment of anemia in adult patients with beta thalassemia; Opdualag for the treatment of unresectable or metastatic melanoma; and Zeposia to treat relapsing forms of multiple sclerosis. In addition, the company offers Breyanzi, a CD19-directed genetically modified autologous T cell immunotherapy for the treatment of adult patients with relapsed or refractory large B-cell lymphoma; Onureg for the treatment of adult patients with AML; Inrebic, an oral kinase inhibitor indicated for the treatment of myelofibrosis; Camzyos for the treatment of adults with symptomatic obstructive HCM to enhance functional capacity and symptoms; Sotyktu for the treatment of adults with moderate-to-severe plaque psoriasis; Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; and Abraxane, a protein-bound chemotherapy product. It sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. The company was formerly known as Bristol-Myers Company. The company was founded in 1887 and is headquartered in New York, New York.
What you need to know about investing in Shein from Australia.
Looking for the best performing stocks in Australia? We update this list weekly.
If you're thinking of trading stocks with Tiger Brokers, check out our review of this online broker's fees, safety and pros and cons first.
Steps to owning and managing Gol Linhas Aéreas Inteligentes SA shares from Australia.
Steps to owning and managing Caltex Australia shares from .
Looking for alternative investments? With a ROI of up to 3,593% lego may be worth considering. Read on to find out which lego sets are worth the investment.
Find cheap stock brokerage in Australia when buying and selling shares on the ASX and other international exchanges.
Learn about the money market and everyday consumer money market products.
Equity crowdfunding offers a unique opportunity for investors and for Australian startups, but Australia’s regulatory framework surrounding crowdfunding still lags behind the rest of the world.
Follow these tips to find the best share trading platform for you.
